Strata Skin科學 SSKN 深 滬
等待開盤 12-12 09:30:00 美东时间
1.47
+0.045
+3.16%
華盛通- 最 高1.52
- 今 開1.40
- 成交量 20.07万股
- 最 低 1.3714
- 昨 收 1.425
- 總市值 865.57万
- 52周最高 3.86
- 市盈率 靜 --
- 換手率 3.41%
- 52周最低 1.24
- 委 比 53.26%
- 總股本 588.82万
- 歷史最高 3480.00
- 量 比 4.29
- 振 幅 10.43%
- 歷史最低 1.24
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ STRATA Skin (SSKN) 业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据STRATA Skin Sciences (SSKN) 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收690万美元，同比下降20%，主要受国际市场挑战影响 - 全球经常性收入550万美元，同比增长3% - 设备收入140万美元，同比大幅下降60% - 美国净经常性XTRAC收入同比增长2.8% - 总代码销售额同比增长4.1% **盈利能力：** - 毛利润420万美元，毛利率60%，与去年同期基本持平 - 净亏损160万美元，每股亏损0.36美元，较去年同期净亏损210万美元（每股亏
11-14 13:03
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
A Peek at Strata Skin Sciences's Future Earnings
Strata Skin Sciences (NASDAQ:SSKN) is preparing to release its quarterly earnin...
11-13 00:03
STRATA Skin Sciences' TheraClearX Treatment For Acne Gets Regulatory Approval From Mexico's Health Authority Through November 2029
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX®
10-28 20:09
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
STRATA Skin Sciences announced that its TheraClearX® acne treatment system has received regulatory clearance from Mexico's COFEPRIS under Device Registration No. 3187E2024SSA, valid through November 2029. This certification is a significant milestone in the company's international expansion strategy, enabling the importation, commercialization, and clinical use of TheraClearX® across Mexico. STRATA has partnered with MINO Labs, a leading Mexican ...
10-28 12:00
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
STRATA Skin Sciences secured a court ruling against LaserOptek, restricting sales and marketing of their laser systems for specific CPT codes and barring false claims. The company regained market share by attracting 20 former LaserOptek clients, generating over $1 million in annual revenue. STRATA expects growth with the expansion of CPT codes to cover more skin conditions, enhancing access for patients and revenue for partners. The company remai...
10-20 12:00
Strata Skin Sciences Announces Equity Distribution Agreement
The latest announcement is out from Strata Skin Sciences ( ($SSKN) ). STRATA Sk...
10-17 05:00
STRATA Skin Sciences Publishes Clinical Case Study On 308-Nm Excimer Laser Use In Rare pMF Subtype Of Cutaneous T-Cell Lymphoma
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to
10-14 20:24
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
<p><p>Strata Skin Sciences announced a groundbreaking clinical case study published in <em>Case Reports in Oncology</em>, demonstrating the successful use of 308-nm excimer laser therapy to treat poikilodermatous mycosis fungoides (pMF), a rare subtype of mycosis fungoides (MF). The study, conducted by researchers at Tohoku University, shows rapid clinical resolution of lesions in a patient with pMF, highlighting the safety and efficacy of the XT...
10-14 12:15
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
STRATA Skin Sciences, Inc. highlights the XTRAC® Excimer Laser as a safe and effective treatment for localized atopic dermatitis, supported by extensive clinical evidence. The American Medical Association has expanded its indications, enabling reimbursement for atopic dermatitis under Medicare, Medicaid, and private insurance. Studies demonstrate significant symptom reduction, improved quality of life, and durability of results. The XTRAC® laser ...
10-03 14:50
